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Vascular endothelial growth factor (VEGF) is a major target for the inhibition of tumour vascularisation and the treatment of human
cancer. Many tumours produce large quantities of VEGF, and as a result, diagnosis and prognosis of cancer may be predicted by
measuring changes in VEGF concentrations in blood. In blood, the VEGF may be located in the plasma, or in the blood-borne cells
and formed elements, in particular, platelets and leukocytes. In this study, we collate the measurements of VEGF in platelets,
leukocytes, plasma and serum for breast, prostate, colorectal and other cancers. In addition, we analysed the concentration of VEGF
in tumour tissue itself, as well as for other tissues in the human body. Although the concentration of VEGF in tumours is high, the size
of tumours is small compared to other tissues, in particular, skeletal muscle. Thus, the total quantity of VEGF in tumours and in blood
is small compared to the quantity in muscles. This large reservoir of VEGF may have important implications for the treatment of
cancer.
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Angiogenesis, the development of new blood vessels from pre-
existing vasculature, has important roles in growth and develop-
ment, wound healing and tumorigenesis. The vascular endothelial
growth factor (VEGF) family of proteins has a pivotal role in
regulating tumour angiogenesis (Shibuya and Claesson-Welsh,
2006).
Vascular endothelial growth factor stimulates cell survival,
migration and differentiation. It induces neovascularisation, and is
required for the establishment of haematopoiesis; in malignant
tumours, VEGF supports development of tumour vessels, which
may lead to increased vascular permeability, and is shown to have
a correlation with cancer prognosis and diagnosis (Folkman, 1995;
Hormbrey et al, 2002).
A marked increase in VEGF levels has been observed in various
types of cancer including anal carcinoma (Kusumanto et al, 2003),
lymphoma (Salven et al, 1999a), lung cancer (Salgado et al, 1999;
Yanagawa et al, 1999; Matsuyama et al, 2000; Kishiro et al, 2002),
gastric carcinoma (Hyodo et al, 1998; Kraft et al, 1999; Yoshikawa
et al, 2000), ovarian cancer (Hyodo et al, 1998; Tempfer et al, 1998;
Kraft et al, 1999; Yoshikawa et al, 2000), renal cell carcinoma
(Dosquet et al, 1997; Sato et al, 1999; Jacobsen et al, 2002;
Ljungberg et al, 2003), brain tumour (Stockhammer et al, 2000),
hepatocellular carcinoma (Poon et al, 2001), breast cancer (Bando
et al, 2005; O’Riain et al, 2005), prostate cancer (Kaushal et al,
2005; Li et al, 2005) and colorectal cancer (Haraguchi et al, 2002;
Karayiannakis et al, 2002; Werther et al, 2003). Of these, the last
three are most extensively studied.
Both breast and prostate cancer are commonly diagnosed
malignancies, and are among the top leading causes of death
responsible for 15 and 10% of cancer deaths in women and men,
respectively in 2005 (Uzzan et al, 2004; Jemal et al, 2005).
Colorectal cancer is responsible for 10% of all cancer deaths in
2005 (Jemal et al, 2005). For all three cancer types, significant
correlations between VEGF and the extent of tumour vascularisa-
tion, tumour stages and metastasis have been reported (Duque
et al, 1999; Gasparini, 2000; Karayiannakis et al, 2002). In addition,
it is reported that the status of oestrogen (ER) and progesterone
(PgR) receptors may have direct correlation with VEGF level in
breast cancer patients (Duque et al, 1999; Gasparini, 2000; Eccles,
2001; Karayiannakis et al, 2002). In recent years, VEGF has been
considered a significant indicator of cancer, and blood VEGF levels
are often used to estimate the degree of tumour development.
However, the debate is still on as to the origin and location of
VEGF. Serum, plasma and whole blood have been commonly used
to determine VEGF levels in the body, but it is not clear which
measurement can provide the best prognostic information. Plasma
is the free circulating, liquid component of blood, in which blood-
formed elements are suspended. Serum is plasma with all
coagulation factors removed, and is obtained by clotting the blood
before centrifugation. Because coagulation results in the release of
VEGF from platelets, serum VEGF concentration counts both
plasma VEGF and platelet-held VEGF.
A number of studies report correlation between platelet counts
and serum VEGF (Werther et al, 2002b; Caine et al, 2004), and
higher serum VEGF levels per platelet in cancer (Salven et al,
1999a; Kusumanto et al, 2003). The importance of platelet-derived
VEGF in cancer may be due to VEGF released upon thrombin
activation by platelets, with VEGF inducing vascular permeability
Received 2 March 2007; revised 19 June 2007; accepted 12 July 2007;
published online 2 October 2007
*Correspondence: F Mac Gabhann; E-mail: feilim@jhu.edu
British Journal of Cancer (2007) 97, 978–985
& 2007 Cancer Research UK All rights reserved 0007– 0920/07 $30.00
www.bjcancer.com
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sand in doing so further promoting coagulation (Mohle et al, 1997;
Verheul and Pinedo, 1998). Other studies suggest that leukocytes
are more important sources of VEGF in cancer patients. A similar
mechanism concerning permeability and thrombin activation has
been postulated to account for the leukocyte–VEGF interaction
(Mohle et al, 1997; Salven et al, 1999a; Kusumanto et al, 2003). To
determine platelet VEGF, values for platelet-rich plasma (PRP) and
platelet-poor plasma (PPP) have been compared; for leukocytes,
the values from a peripheral blood mononuclear cell suspension
(PBMNC) have been obtained.
Studies on VEGF levels in urine (Bok et al, 2001), pleural effusion
(Kraft et al, 1999; Thickett et al, 1999; Yanagawa et al, 1999; Kishiro
et al, 2002; Toi et al, 2002), tumour cytosol (Obermair et al, 1997;
Eppenberger et al, 1998; Baker et al, 2000; Broll et al, 2001; Foekens
et al, 2001; Haraguchi et al, 2002; Toi et al, 2002; Manders et al,
2003; Desruisseau et al, 2004; Bando et al, 2005), tumour cyst fluid
(Stockhammer et al, 2000) and other body fluids are available.
However, most do not have a basis of comparison, as they report
only the VEGF levels in cancer patients, but no control equivalent
in healthy volunteers. It may be possible to compare some of these
to values in healthy individuals from other studies.
The inhibition of VEGF expression and signalling in tumours is
a promising therapeutic strategy. Tumour-induced angiogenesis is
largely dependent on VEGF, and studies have demonstrated that
anti-VEGF antibodies successfully inhibit both angiogenesis and
tumour growth (Eatock et al, 2000). The first anti-VEGF drug,
bevacizumab, was approved by Food and Drug Administration in
2004. In all phase trials, the drug was reported to be well-tolerated,
and increased the response and survival rates of patients (Tortora
et al, 2004).
In contrast to VEGF inhibition in tumours and other diseases,
administration of additional VEGF could potentially treat dis-
orders that result in restricted or limited blood supply. For
example, it may be a therapeutic agent for chronic limb ischaemia,
which is often caused by obstructive atherosclerosis and has a high
mortality rate; other potential therapeutic applications include the
treatment of coronary insufficiency and restenosis (Ferrara and
Davis-Smyth, 1997).
Understanding the distribution of VEGF in human body is vital
to the prognosis and treatment of cancer and other disorders. It is
especially important for designing and understanding anti-VEGF
therapeutics. However, important variations across studies, includ-
ing methods of sample collection, patient selection, measurement
units, statistical analysis and data interpretation, make it difficult to
obtain a global view of VEGF distribution. To our knowledge, there
has been no comprehensive review of the literature that elucidates
the relative concentrations of VEGF in such body compartments as
blood, normal tissues and organs, and tumour, nor one that gives
detailed overview of VEGF levels across various cancer types. The
present study aims to review previously reported VEGF levels and
summarise the results in the form of VEGF localisation to various
body compartments. An additional motivation and aim of the
present study is to provide a solid basis for quantitative, systems
biology studies of the VEGF system in health and disease (Mac
Gabhann and Popel, 2006; Mac Gabhann et al, 2006).
METHODS
Publication selection
Meta-analysis was based on an electronic literature search through
Pubmed and Google Scholar. Key words used included: vascular
endothelial growth factor; VEGF; cancer; breast; prostate; color-
ectal; serum; plasma; platelets; and leukocytes. Papers were also
found through the references and citations of all the relevant
studies. To be included in our meta-analysis, papers had to be in
vivo studies, included in the Pubmed database, deal with cancer
patients and present quantitative VEGF data. Studies with aberrant
data (over a 10-fold difference than those reported in other papers)
were also excluded. Based on these criteria, 12 studies were
excluded from our collection (Liu et al, 1999; Haggstrom et al,
2000; Bhujwalla et al, 2001; Feldman et al, 2001; George et al, 2001;
Huss et al, 2001; Kelavkar et al, 2001; Calvo et al, 2002; Mabjeesh
et al, 2003; Cianchi et al, 2004; Singh et al, 2004; May et al, 2005)
(Supplementary Table S6).
Information extraction
The following items were extracted from each paper: type of
cancer, sample size, location of VEGF measured, VEGF isoform
studied, methodology of data collection, VEGF diagnosis, statis-
tical format, platelet/leukocyte count and the mean or median
value for both healthy and cancer VEGF concentration. If the paper
presented VEGF data in several categories and failed to report an
overall cancer VEGF value, data estimation (indicated by an
asterisk * in Supplementary Tables S1–S4, online supplement) was
performed taking the average of data in all categories. Our analysis
was performed by comparing results from individual papers. We
did not amend the statistical analyses used in each paper.
Vascular endothelial growth factor measurement
methods used
Both plasma and serum have been commonly used to determine
VEGF levels in the blood. From our reviewed literature, peripheral
venous blood samples were drawn. To prepare plasma, blood
samples were put in test tubes with an anticoagulant (either
trisodium citrate or ethylenediaminetetraacetic acid). The test tubes
were then left for 0–30min before centrifugation, 1000–3000 g at
4–211C for 10–20min. To prepare serum, blood samples were put
in sterile silicone-coated tubes without additive, or serum
separator/clot activator test tubes. Blood samples were then allowed
to clot for 30–120min before centrifugation, 1000–3000 g at
4–211C, for 7–15min (one paper reported a centrifugation rate of
16000 g). Both plasma and serum samples were subsequently
aliquoted and stored at  20 to  801C before assay.
To obtain tumour cytosol measurements, tumour tissues
obtained during surgery were immediately frozen in liquid
nitrogen. To prepare the samples, the tissue samples were diluted
in a buffer. The tissues were then either homogenised with Ultra
Terrex, pulverised with microdismembrator or diced with a
scalpel. The homogenised tissue samples were then centrifuged
at 800–105000 g, for 15–60min. The resulting supernatant
(tumour cytosol) was then stored at  70 to  801C until analysis.
Enzyme-linked immunosorbent assay (ELISA) was the adopted
assay type for 74% of the studies. Among those using ELISA, 40%
obtained the assay kit from R&D Systems, (Minneapolis, MN,
USA). The remaining 60% used kits from 14 other different
companies. Five other different assay types were also used,
including quantitative sandwich enzyme immunoassay, enzyme
immunoassay, chemiluminescence immunosorbent assay, human
VEGF immunoassay quantigo kit and immunofluorometric assay.
Data analysis
The weighted average and s.d. of VEGF concentrations were
evaluated in all cancer studies for various compartment of the
body (serum, plasma, whole blood and tumour cytosol). Our
calculations were based on the following equations:
WeightedaverageðxavgÞ¼
X
ðni   xiÞ=
X
ni
Weightedstandarddeviation ¼
X
ni  ð xi   xavgÞ
2=
X
ni
ni: number of subjects reported in each paper; xi, VEGF level
reported in each paper.
Meta-analysis of VEGF distribution in cancer
C Kut et al
979
British Journal of Cancer (2007) 97(7), 978–985 & 2007 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sA two-sample, one-tailed Student’s t-test was used. A probability
of o0.05 was taken to be significant. The overall statistical meta-
analysis is given in Table 1. In our meta-analyses, units were
reported in pgml
 1,p gm g
 1 protein, pg10
 6 cells, 10
6cellsml
 1.
Unit conversion was performed whenever necessary. Concentra-
tions are rounded to whole numbers.
RESULTS AND DISCUSSION
Study selection
Our literature search identified 64 references containing quanti-
tative information to be included in this analysis, including 19
breast cancer, 13 prostate cancer, 13 colorectal cancer and 19 other
cancer studies. Details for each of these studies are given in
Supplementary Table S1 for breast cancer (Yamamoto et al, 1996;
Obermair et al, 1997; Salven et al, 1997, 1999b; Verheul et al, 1997;
Eppenberger et al, 1998; Adams et al, 2000; Foekens et al, 2001;
Heer et al, 2001; Colleoni et al, 2002; Toi et al, 2002; Caine et al,
2003; Manders et al, 2003; Desruisseau et al, 2004; Granato et al,
2004; Sancak et al, 2004; Zhao et al, 2004; Bando et al, 2005;
O’Riain et al, 2005), Supplementary Table S2 for prostate cancer
(Joseph et al, 1997; Salven et al, 1997; Bauer et al, 1999; Duque
et al, 1999; Jones et al, 2000; Bok et al, 2001; Figg et al, 2001; Caine
et al, 2003, 2004; Kohli et al, 2003; George et al, 2004; Kaushal et al,
2005; Li et al, 2005), Supplementary Table S3 for colorectal cancer
(Dirix et al, 1996; Hyodo et al, 1998; Kumar et al, 1998; Baker et al,
2000; Chin et al, 2000; Davies et al, 2000; George et al, 2000; Broll
et al, 2001; Haraguchi et al, 2002; Karayiannakis et al, 2002;
Werther et al, 2002a,b, 2003) and Supplementary Table S4 for
other cancers (Yeo et al, 1993; Dosquet et al, 1997; Hyodo et al,
1998; Tempfer et al, 1998; Viac et al, 1998; Kraft et al, 1999;
Salgado et al, 1999; Sato et al, 1999; Thickett et al, 1999; Yanagawa
et al, 1999; Salven et al, 1999a; Matsuyama et al, 2000;
Stockhammer et al, 2000; Yoshikawa et al, 2000; Tabone et al,
2001; Jacobsen et al, 2002; Kishiro et al, 2002; Kusumanto et al,
2003; Ljungberg et al, 2003).
Cancer studies and meta-analysis
Breast cancer The main results on healthy and cancer VEGF
levels are summarised in Supplementary Table S1 and Figures 1A,
2A and B. Serum VEGF levels in cancer patients appear to be about
two times higher than those in healthy controls (range: 92–390 vs
17–287pgml
 1). Plasma VEGF levels have a range of 37–
310pgml
 1 (cancer) vs 27–30pgml
 1 (healthy). Tumour cytosol
VEGF values range from 140 to 693pgmg
 1 protein, but there is
no control equivalent in healthy subjects or other tissues in these
studies. We will compare these values with measurements from
other tissues reported in other studies.
The relationship between VEGF in cancer and expression of
hormone receptors for oestrogen and progesterone was also
examined. Serum values appear to be slightly higher for both
positive ER and PgR status, although the difference does not
appear to be significant (ER status: 75–271 (negative) vs 90–
298pgml
 1 (positive); PgR status: 75–141 (negative) vs 89–
187pgml
 1 (positive)). However, both ER and PgR tumour cytosol
values deviate from the above data, where ER-negative values are
1.5–2 times higher than ER-positive values (360–700 vs 180–
560pgmg
 1 protein) and PgR-negative values are 1.5 times higher
than PgR-positive values (289–760 vs 212–510pgmg
 1 protein).
Prostate cancer Results are summarised in Supplementary Table
S2 and Figures 1B and 2B. Vascular endothelial growth factor level
is 2–3 times higher in serum, and 3–10 times higher in plasma of
cancer patients (serum: 129–323 cancer vs 17–171pgml
 1
(healthy); plasma: 32–730 cancer vs 13–61pgml
 1 (healthy)).
Colorectal cancer Results are summarised in Supplementary
Table S3 and Figures 1C, 2A and B. Both serum and plasma VEGF
are about two times higher in cancer patients (serum: 66–563
cancer vs 173–391pgml
 1 (healthy); plasma: 19–211 cancer vs 9–
126pgml
 1 (healthy)). Whole blood values are relatively high
(597–700 cancer vs 506pgml
 1 (healthy)), although results may
have been skewed with only two studies involved. Tumour cytosol
values range from 189 to 984pgmg
 1 protein, which are
approximately 1.5 times higher than those in breast cancer studies.
Other cancer types Results are summarised in Supplementary
Table S4 and Figure 1D. When compared to healthy VEGF, cancer
VEGF is elevated by approximately 2–4 times for serum values,
and by 2–6 times for plasma values (serum: 207–681 cancer vs
51–318pgml
 1 (healthy); plasma: 23–137 cancer vs 9–26pgml
 1
(healthy)). For whole blood VEGF, cancer values are again higher
when compared to serum and plasma data (461–1435 cancer vs
298–301pgml
 1 (healthy)).
Table 1 Weighted average VEGF of all cancer studies
n*
Serum
(pgml
 1) s.d. n
Plasma
(pgml
 1) s.d. n
Whole blood
(pgml
 1) s.d. n
Tumour cytosol
(pgmg
 1 protein) s.d.
Breast cancer
Healthy 371 (6) 119 83 75 (2) 28 1 NA NA NA NA NA NA
Cancer 883 (11) 222 101 168 (2) 85 105 NA NA NA 1797 (7) 329 159
Prostate cancer
Healthy 29 (2) 129 70 540 (3) 47 8 NA NA NA NA NA NA
Cancer 104 (4) 281 74 771 (6) 87 153 NA NA NA NA NA NA
Colorectal cancer
Healthy 390 (6) 193 55 147 (4) 35 40 24 (1) 506 NA 115 (2) 62 31
Cancer 931 (9) 363 115 553 (5) 46 36 75 (2) 630 48 119 (3) 612 366
Other cancers
Healthy 290 (7) 238 91 33 (2) 19 8 69 (2) 299 1 NA NA NA
Cancer 901 (13) 399 137 87 (3) 104 27 56 (2) 533 252 NA NA NA
All cancers
Healthy 1080 (21) 173 90 825 (12) 42 20 93 (3) 352 91 115 (2) 62 31
Cancer 2833 (37) 328 139 1579 (16) 74 116 131 (4) 589 175 1916 (10) 334 184
*Total number of patients (number of papers). Abbreviation: VEGF¼vascular endothelial growth factor.
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sSummary Results are summarised in Table 1 and Figure 1A–D.
When compared to the ranges of healthy VEGF levels, reported
cancer VEGF ranges are about twice as large. The ranges of
reported healthy values of VEGF are mostly comparable. Within all
groups, the weighted average of normal VEGF is lower than that of
the cancer values. Between the groups, however, the average
healthy VEGF can be comparable to cancer levels in other groups.
For example, average healthy serum VEGF in the other cancer
studies is slightly higher than average breast cancer serum VEGF
(238 vs 222pgml
 1).
Compartmental analysis and data interpretation
Blood compartment To evaluate VEGF distribution in the body,
we combined all the studies and derived the average VEGF
concentration for serum and plasma. To determine the total
quantity of serum or plasma VEGF in the body, we multiplied
concentrations by the total volume of serum or plasma, 2.26l, as
explained below (Lentner et al, 1984). Based on this analysis, we
evaluated the quantity of VEGF in serum to be 4.3 (healthy) and
4.4 (cancer) times higher than the quantity of VEGF in plasma. The
results are summarised in Figure 3A and B.
Vascular endothelial growth factor evaluation for platelets is
based on two types of measurements: plasma-corrected VEGF/
platelet values from Salven et al (1999b); George et al (2000); and
PRP measurements from Kusumanto et al (2003) and Salven et al
(1999a). We excluded reference Caine et al (2004) because the data
reported was three orders of magnitude higher than those reported
in other studies. Concentrations are calculated using volume of a
platelet, 9fl (Lentner et al, 1984), and quantity is determined by
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Figure 1 Vascular endothelial growth factor (VEGF) levels in the blood of cancer patients and healthy volunteers. (A) Breast cancer studies. (B) Prostate
cancer studies. (C) Colorectal cancer studies. (D) Other cancer studies. Weighted average for VEGF values denoted by a bar in the graph. *Po0.001
greater than healthy controls.
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Figure 2 Intratumoural VEGF levels and platelet and leukocyte numbers. (A) Tumour cytosol VEGF levels. Colorectal tumour cytosol VEGF values are
approximately 1.5 times higher than those in breast cancer studies. (B) Platelet count and leukocyte count in cancer studies. *Po0.001 greater than healthy
controls.
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smultiplying the concentration by the total volume of platelets in
the blood (cancer: 14.18ml, healthy: 11.15ml) (Lentner et al,
1984; Werther et al, 2002b). Results are summarised in Figure 3A
and B. Total quantity of VEGF in platelets is 6.5 times than that in
serum, and 28.2 times higher than that in plasma for cancer
patients.
Vascular endothelial growth factor is sequestered in the
alpha granules of platelets at a high concentration. It has been
suggested that platelets might recycle the VEGF they
have scavenged, since the VEGF concentration increases in
platelets over time for as long as the VEGF source is present
(Folkman, 2007). The mechanisms underlying the VEGF seques-
tration, however, are not well established. Further research is
necessary to determine how platelets contribute to the VEGF
upregulation in cancer.
Leukocyte VEGF values are determined using PBMNC values
from Salven et al (1999a). We took the average of granulocyte,
lymphocyte and monocytes volumes, 383fl per cell (Lentner et al,
1984). We also calculated the total leukocyte volume in blood
(cancer: 13.41ml, healthy: 9.97ml) (Lentner et al, 1984; Werther
et al, 2002b). Results are shown in Figure 3A and B. We observe a
low quantity of healthy leukocyte VEGF when compared to plasma,
serum and platelet levels. However, the difference between healthy
and cancer quantities is the highest. The quantity of VEGF in
leukocytes in cancer is 18.5 times higher than that in healthy,
which is 10 times the increase in plasma, serum or platelet VEGF in
cancer.
Tumour compartment We evaluated the average VEGF level in
tumour cytosol from the collected data in units of pgmg
 1 protein.
Concentration (pgml
 1) was estimated using a protein mass ratio
of 160mg proteing
 1 fat-free tissue and tissue density of 1.06g
tissueml
 1 (Lentner et al, 1981). We calculated the total quantity
of VEGF based on 100 and 1000g tumours. Results are
summarised in Figure 3A and B.
We observe that the quantity of VEGF in the tumours is 7–70
times higher than the quantity in serum, 31–306 times higher than
plasma quantity, 1.1–10.8 times higher than platelet quantity and
14–141 times higher than leukocyte quantity. This indicates that
tumour tissue is a significant source and reservoir for VEGF in a
cancer patient.
Vascular endothelial growth factor content of normal tissues There
is no standard control for tumour cytosol VEGF levels. Vascular
endothelial growth factor levels in the normal colon tissues
of cancer patients were evaluated (Baker et al, 2000; Broll et al,
2001). Vascular endothelial growth factor quantities in skeletal
muscle (human vastus lateralis) (Gavin et al, 2004) and rat
muscle, for comparison (Zhang et al, 1997) were also evaluated;
muscle VEGF content is particularly important since it constitutes
close to half the mass of the human body. Vascular endothelial
growth factor concentration (pgml
 1) in these tissues was
estimated using a protein mass ratio of 160mg proteing
 1 fat-
free tissue and tissue density of 1.06g tissueml
 1 (Lentner et al,
1981).
Vascular endothelial growth factor concentration in normal
colon tissues and skeletal muscle ranged between 27.3 and
1500pgmg
 1 protein or 4630 and 254400pgml
 1 tissue. The total
body mass of VEGF can be evaluated using the above data, the
body mass of a 30–39-year-old male (78kg), the volume of blood
(5l) and the density of blood (1060kgm
 3). Assuming that the
body consisted only of tissue and blood, we estimated the total
VEGF to be between 318 and 17448mg.
Vascular endothelial growth factor level in other tissues in rats
have been reported in units of pgmg
 1 tissue (Eccles, 2001).
Assuming human tissue concentrations similar to these rat
concentrations, and using the mass of human organs (Lentner
et al, 1981), the total quantity of VEGF in each organ was predicted
as 1.8mg in heart, 6.7mg in liver, 30.6mg in lungs, 2.4mg in kidney
and 14.6mg in brain. It thus appears that, of the healthy tissues,
skeletal muscle contains the most VEGF.
Compared to the total mass of VEGF in the human body,
tumour contributes to a relatively small percentage of VEGF
(0.03–2% for 100g tumour, 0.3–16% for 1kg tumour). This may
indicate that VEGF is more readily compartmentalised in blood
and muscle. Further research will be needed to determine how
VEGF is concentrated and transported in each of the compart-
ments of the body.
Free VEGF concentration in healthy and tumour tissues The
concentration of free (unbound) VEGF in the interstitial space of
human breast tumour and muscle vastus lateralis have been
measured using microdialysis. For both tissues, this concentration
is in the range of 0.5–1.5pM (Dabrosin et al, 2002, 2003; Hoffner
et al, 2003), or 23–68pgml
 1 interstitial space, or 1.6–4.8pgml
 1
tissue (skeletal muscle), 13.3–39.4pgml
 1 tissue (breast tumour).
Note that the extracellular concentration is similar to the plasma
concentration (Figure 3A), suggesting that plasma VEGF and
interstitial VEGF are close to being at equilibrium as VEGF moves
across the endothelial barrier of the vasculature. Our computa-
tional models of VEGF transport in vivo predict that this free
VEGF accounts for approximately 1% of the total extracellular
VEGF in the tissue (extracellular VEGF comprises free, extra-
cellular matrix-bound and cell surface receptor-bound) (Mac
Gabhann and Popel, 2007). Thus, there is approximately 160–
480pgml
 1 tissue extracellular VEGF in the muscle, or 5.1–15.2mg
in total. This suggests that the remaining (i.e., most of VEGF in the
body—approximately 8000mg in skeletal muscle alone, based on
concentrations in human vastus lateralis, Gavin et al, 2004) is
located intracellularly.
Other VEGF measurements Elevated VEGF is also noted in other
angiogenic environments. For example, in wound healing, VEGF
concentration in the wound fluid is several fold the plasma or
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Figure 3 Vascular endothelial growth factor (VEGF) distribution in the body. (A) Concentrations of VEGF in the body. Average VEGF concentrations are
recorded for platelets, leukocytes and the blood compartment for both healthy and control values. (B) Quantities of VEGF in the body. Average VEGF
quantities are recorded for platelets, leukocytes and the blood compartment for both healthy and control values. (C) Comparison of blood VEGF quantities
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sserum concentration (Hormbrey et al, 2003; Karayiannakis et al,
2003; Wu et al, 2003; Di Vita et al, 2006). In bone marrow fluid,
VEGF levels increase from 1.5 to 4pM in acute leukaemia patients
(Ye et al, 2003).
Vascular endothelial growth factor levels have also been
reported in cancer-associated effusions. Vascular endothelial
growth factor concentrations in pleural effusions is about three
times higher in cancer patients (of various types of cancer) than in
healthy subjects (cancer: 2929pgml
 1, healthy: 930pgml
 1) (Kraft
et al, 1999; Thickett et al, 1999; Yanagawa et al, 1999; Matsuyama
et al, 2000; Kishiro et al, 2002). In peritoneal effusions, VEGF
values increases from about 20 to 31pmoll
 1 in cancer patients (of
various types of cancer) (Yeo et al, 1993). In these two types of
effusions, multiple types of cancer patients are involved (Supple-
mentary Table S3, Online Supplement). In pericardial effusions,
lung cancer VEGF levels are about 40-fold the healthy VEGF level
(cancer: 3072pgml
 1, control: 81pgml
 1) (Matsuyama et al,
2000).
Vascular endothelial growth factor secreted from various tissues
will eventually be cleared by the kidney. Urine VEGF values
have been reported to be higher in cancer patients when compared
to healthy controls (Eisen et al, 2000; Bok et al, 2001).
Renal clearance of VEGF could be responsible for changing VEGF
levels in the blood compartment. Future mechanistic studies
should delineate whether increased VEGF in plasma of cancer
patients is caused by the increased VEGF secretion by tumour and
bone marrow cells, or by the altered rates of VEGF clearance from
the kidneys.
CONCLUSION
Our results provide an integrative analysis of VEGF levels in
various compartments of the body in cancer patients and address
important issues in VEGF data interpretation. Conclusions drawn
from VEGF values in different cancer types were consistent.
Within the blood compartment, VEGF is mostly concentrated in
the platelets, although a significant portion was localised in
leukocytes during cancer development. Large quantities of VEGF
were reported in tumour and skeletal muscle, the latter of which
suggested an intracellular VEGF source.
The most surprising result of this analysis is that even in cancer,
tumours are not the largest source of VEGF in the body. Other
tissues, and in particular skeletal muscle, appear to contain a large
reservoir of VEGF, and this should be a consideration in the design
of cancer therapeutics. For example, the systemic administration of
anti-VEGF antibodies may have to overcome the effects of a large
non-tumour-derived VEGF reservoir.
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